Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.

Pretoria - The Gauteng High Court, Pretoria, finally issued an order yesterday allowing for medicine that contained ivermectin as an active ingredient to also be used for the treatment of Covid-19 if so prescribed by a doctor.

Ivermectin, a broad-spectrum anti-parasitic that also has anti-inflammatory activity, has shown remarkable success in preventing and treating COVID-19.

George W. Merck set the standard for his company when he announced, “We try to never forget that medicine is for the people. It is not for the profits. The profits follow, and if we remembered that, they have never failed to appear.”

READ HERE

After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.

On 22 March, the European Medicines Agency (EMA) issued a statement [0] that, after reviewing the evidence, they recommend against the use of ivermectin for the prevention and treatment of covid-19, outside of ‘well-designed’ clinical trials.

At a March 18, 2021 press conference, a group of medical and scientific experts convened by the Front Line COVID-19 Critical Care Alliance (FLCCC) called for action to put an end to the COVID-19 pandemic by immediately adopting policies that allow for the use of ivermectin in the prevention and treatment of COVID-19.